^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

troculeucel (SNK01)

i
Other names: SNK01, autologous NK cell adoptive immunotherapy, SNK-01, Super Natural Killer Cells 01, autologous non-genetically modified natural killer cells with enhanced cytotoxicity
Company:
NKMAX
Drug class:
NK cell stimulant
Related drugs:
9ms
Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers (clinicaltrials.gov)
P1/2, N=11, Terminated, NKGen Biotech, Inc. | N=121 --> 11 | Trial completion date: Nov 2025 --> Sep 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Nov 2025 --> Sep 2023; Affimed and NKGen have mutually decided to discontinue the study. Affimed will evaluate the best options to advance this project with an allogeneic off-the-shelf NK cell product while NKGen will focus on CNS with SNK01.
Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Combination therapy • Metastases
|
EGFR expression • EGFR wild-type • EGFR positive
|
troculeucel (SNK01) • AFM24
9ms
Safety of SNK01 in Subjects With Alzheimer's Disease (ASK-AD) (clinicaltrials.gov)
P1, N=10, Terminated, NKGen Biotech, Inc. | N=30 --> 10 | Recruiting --> Terminated | Trial primary completion date: Dec 2023 --> Aug 2023; The study was terminated after completing the dose escalation portion of the study. The expansion cohort was not initiated to conduct a global trial based on the approved US IND using a new manufacturing process.
Enrollment change • Trial termination • Trial primary completion date
|
troculeucel (SNK01)
11ms
New P1/2 trial • IO biomarker
|
troculeucel (SNK01)
1year
Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy (clinicaltrials.gov)
P1, N=27, Completed, NKGen Biotech, Inc. | Active, not recruiting --> Completed | Trial completion date: Sep 2023 --> Feb 2023
Trial completion • Trial completion date • Metastases
|
Keytruda (pembrolizumab) • Bavencio (avelumab) • troculeucel (SNK01)
1year
Treatment of Alzheimer's Disease Subjects With Expanded Non-genetically Modified Natural Killer Cells (SNK01) With Enhanced Activity — Final Report of a Phase I Dose Escalation Study (CTAD 2023)
SNK01 was safe and well tolerated. SNK01 appears to have clinical activity in AD while reducing neuroinflammation and protein levels. These results justify a larger trial with a higher dosing and longer treatment duration which will be initated in late 2023.
Clinical • P1 data
|
troculeucel (SNK01)
over1year
Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy (clinicaltrials.gov)
P1, N=27, Active, not recruiting, NKGen Biotech, Inc. | Trial completion date: May 2023 --> Sep 2023
Trial completion date • Metastases
|
Keytruda (pembrolizumab) • Bavencio (avelumab) • troculeucel (SNK01)
over2years
Two-year efficacy of SNK01 plus pembrolizumab for non-small cell lung cancer: Expanded observations from a phase I/IIa randomized controlled trial. (PubMed, Thorac Cancer)
Autologous NK cells can enhance the long-term OS and PFS for NSCLC. A larger study is needed to confirm this result. Clinical Research Information Service number: KCT0003463.
P1/2 data • Journal
|
PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab) • troculeucel (SNK01)
over2years
The combination of CD16A/EGFR innate cell engager, AFM24, with SNK01 autologous natural killer cells in patients with advanced solid tumors. (ASCO 2022)
Efficacy will also be assessed by assessing progression-free and overall survival. Secondary endpoints for both phases include treatment-emergent adverse events, serious adverse events, pharmacokinetics and immunogenicity.
Clinical
|
EGFR (Epidermal growth factor receptor) • FCGR3A (Fc Fragment Of IgG Receptor IIIa)
|
troculeucel (SNK01) • AFM24
almost3years
A Phase I/IIa Randomized Trial Evaluating the Safety and Efficacy of SNK01 Plus Pembrolizumab in Patients with Stage IV Non-Small Cell Lung Cancer. (PubMed, Cancer Res Treat)
Furthermore, the median PFS was higher in the SNK01 combination group (6.2 vs. 1.6 months; p=0.001). Based on the findings of this study, the NK cell combination therapy may consider as a safe treatment method for stage IV NSCLC patients who had a history of failed platinum-based therapy without an increase in adverse events (AEs).
Clinical • P1/2 data • Journal
|
PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab) • troculeucel (SNK01)
almost3years
PHASE 1 STUDY OF ESCALATING DOSES OF EX VIVO EXPANDED, AUTOLOTOUS NATURAL KILLER CELLS IN PATIENTS WITH PATHOLOGICALLY CONFIRMED CANCER REFRACTORY TO CONVENTIONAL THERAPY [NCT03941262] (CTOS 2021)
After completing the 3 Cohorts of single dose escalation of SNK01, the protocol was amended to include Cohort 4 (n=18) wherein SNK01 is given in combination with an immune checkpoint inhibitor (avelumab or pembrolizumab). The trial is currently in progress and 16/18 patients have been enrolled to date.
P1 data • Preclinical • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • NKG2D (killer cell lectin like receptor K1)
|
PD-L1 negative
|
Keytruda (pembrolizumab) • Bavencio (avelumab) • troculeucel (SNK01)
over3years
Clinical • Enrollment open • Combination therapy
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
EGFR mutation • ALK mutation • ROS1 mutation
|
Erbitux (cetuximab) • carboplatin • gemcitabine • troculeucel (SNK01)
over3years
Clinical • Preclinical • Enrollment change • Trial withdrawal • Combination therapy
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
|
Herceptin (trastuzumab) • Erbitux (cetuximab) • troculeucel (SNK01)
over3years
Clinical • New P1/2 trial • Combination therapy
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
EGFR mutation • ALK mutation • ROS1 mutation
|
Erbitux (cetuximab) • carboplatin • gemcitabine • troculeucel (SNK01)
almost4years
Clinical • Preclinical • Trial initiation date • Combination therapy
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
|
EGFR positive
|
Herceptin (trastuzumab) • Erbitux (cetuximab) • troculeucel (SNK01)
over4years
[VIRTUAL] A randomized phase I/IIa study to evaluate the safety and efficacy of SNK01 (non-genetically modified autologous natural killer cells with enhanced cytotoxicity) plus pembrolizumab in patients with stage IV non-small cell lung cancer. (ASCO 2020)
These preliminary results demonstrate that combination therapy with Pembrolizumab and SNK01 is very safe and even appears to reduce checkpoint associated toxicity while increasing overall tumor response compared to Pembrolizumab monotherapy alone in Stage IV NSCLC patients who have failed prior platinum-based treatment. Research Funding: NKMAX
Clinical • P1/2 data
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab) • troculeucel (SNK01)
over4years
[VIRTUAL] Use of SNK-01 (Autologous Non-Genetically Modified Natural Killer Cells with Increased Cytotoxicity) in Combination with Pembrolizumab in Solid Tumors to Improve Tumor Response and Decrease Checkpoint Inhibitor Related Toxicity. (NIH-AACR Immunology 2020)
These preliminary results demonstrate that combination therapy with Pembrolizumab and SNK01 is very safe and even appears to significantly reduce checkpoint associated toxicity while increasing overall tumor response compared to previously reported Pembrolizumab monotherapy alone results in patients with advanced solid tumors. We plan to investigate this further with a much umbrella larger study.
Combination therapy • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • APP (Amyloid Beta Precursor Protein)
|
PD-L1 expression
|
Keytruda (pembrolizumab) • troculeucel (SNK01)